Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Table 7 Sensitivity analysis: 1-year budget impact analysis of DEX, BORT and LEN/DEX

Sensitivity parameter	Total costs
Sensitivity parameter	Low estimate (% change from base case)	High estimate (% change from base case)
Unit cost: LEN/DEX (R446,68-R2233,38) BORT (R288,49-R2442,45)	R 41 047 217 (−66%)	R 200 302 026.11 (+ 66%)
	R 16 564 932 (−63%)	R 97 981 213.28 (+ 120%)
Population coverage: LEN/DEX (50%-80%) BORT (50%-80%)	R 48 269 850 (−60%)	R 96 539 700 (+ 20%)
Population coverage: LEN/DEX (50%-80%) BORT (50%-80%)	R 17 784 486 (−60%)	R 35 568 972 (+ 20%)
Uptake rate: LEN/DEX (50%) + DEX (50%)	R 48 819 379 (−60%)	R 96 814 464 (+ 20%)
BORT (80%) + DEX (20%)	R 18 334 015 (−59%)	R 35 843 737 (+ 19%)

ISSN: 1478-7547